Datasea Announces Strategic Collaboration with a Leading Brain-Computer Interface Company in China

Rhea-AI Summary

Datasea (OTC:DTSS) announced on January 5, 2026 a strategic collaboration between its China subsidiary Datasea Jingwei and Nanjing Linghang Intelligent Aviation Technology to explore applying Datasea's acoustic enhancement technologies to non-invasive brain–computer interface (BCI) and healthcare robot systems.

The agreement covers system integration validation, engineering testing, and application exploration aimed at improving EEG signal stability and decoding accuracy, supporting future productization for rehabilitation and healthcare services. The release cites industry forecasts that the global BCI market could reach USD 15–20 billion by 2030.

Positive

• Collaboration agreement executed on January 5, 2026
• Target market projected at USD 15–20 billion by 2030
• Datasea reports completed acoustic prototypes and patent layouts
• Linghang products validated across hospitals and care institutions

Negative

• None.

Argus Jan 5 session

+21.27% close to close Open Argus

Details

News Market Reaction – DTSS

In the Jan 5 session, DTSS gained 21.27%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +21.3% in the session following this news. A strong positive reaction aligns with D...

Analysis

The stock surged +21.3% in the session following this news. A strong positive reaction aligns with Datasea’s ongoing shift toward acoustic and BCI technologies, echoing prior gains after BCI-related updates. However, past record revenue and partnership news also preceded declines, underscoring historically inconsistent follow‑through. Investors could weigh how quickly this collaboration translates into validated products and contracts, while recognizing that prior filings cited going‑concern risks and reliance on external financing, which may temper the durability of any sharp move.

Key Figures

Global BCI market size: USD 15–20 billion Market outlook year: 2030 Report year: 2024 +1 more

Global BCI market size

USD 15–20 billion

Expected by 2030 per 2024 industry research reports

Market outlook year

2030

Horizon for global brain–computer interface market projections

Report year

2024

Publication year of cited Grand View Research and Fortune Business Insights reports

Primary demand horizon

Next decade

Expected growth period for rehabilitation, consumer electronics, wearables

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Strategic partnership

   24h Move

   -3.1%

   Acoustics + AI health system rollout with revenue-sharing terms in China.

2. Dec 11

   BCI tech update

   24h Move

   +14.6%

   Engineering completion of two acoustic-driven BCI systems for signal enhancement.

3. Nov 18

   Market activity note

   24h Move

   +14.5%

   Statement on normal operations and highlighting Q1 gross profit improvement.

4. Nov 13

   Quarterly earnings

   24h Move

   -4.0%

   Revenue decline alongside sharp gross profit and margin improvement from tech focus.

5. Sep 26

   Annual results

   24h Move

   -10.2%

   Record FY2025 revenue and gross profit with expansion in AI and acoustic segments.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

brain–computer interface, eeg, neuromodulation, closed-loop, +1 more

5 terms

brain–computer interface medical

"a leading China-based enterprise specializing in brain–computer interface ("BCI") research"

A brain–computer interface is a technology that reads signals from a person’s brain and translates them into commands a computer or machine can understand, allowing direct control without physical movement. For investors, it matters because successful BCI products can create new markets in healthcare, assistive devices, and consumer electronics, similar to how touchscreens opened whole industries; they carry high potential returns but also technical, regulatory, and ethical risks that affect company value.

eeg medical

"including insufficient EEG signal stability and limited signal decoding accuracy"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

neuromodulation medical

"extension of its core acoustic technologies into the fields of neuromodulation and intelligent interaction"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

closed-loop technical

"sound-wave coupling enhancement mechanisms and real-time closed-loop vibration modulation methods"

A closed-loop system automatically measures its own output and feeds that information back to adjust inputs, operating without the need for constant human intervention — like a thermostat that senses room temperature and turns the heater on or off to keep a set point. Investors pay attention because closed-loop products often deliver more consistent performance, lower operational costs, and stronger regulatory or competitive advantages, which can improve revenue prospects, margins and risk profiles for companies that make or use them.

healthcare robotics technical

"focused on BCI technologies, healthcare robotics, and scenario-based system solutions"

Healthcare robotics are machines and automated systems designed to perform medical tasks such as assisting surgery, delivering supplies, helping patients move, or providing rehabilitation and monitoring. They matter to investors because they can improve outcomes, reduce labor costs, and scale services much like a faster, steadier set of hands in a hospital; adoption, regulatory approval, and reimbursement determine how quickly those efficiency and revenue gains translate into profits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Acoustic Enhancement Technology Expands into the Multi-Billion-Dollar Non-Invasive BCI and Healthcare Applications Market

BEIJING, Jan. 5, 2026 /PRNewswire/ -- Datasea Inc. (the "Company" or "Datasea") today announced that its China operating subsidiary, Datasea Jingwei Information Technology Co., Ltd., has entered into a strategic collaboration agreement with Nanjing Linghang Intelligent Aviation Technology Co., Ltd., a leading China-based enterprise specializing in brain–computer interface ("BCI") research and product applications.

Pursuant to the agreement, the parties will explore the application of Datasea's acoustic enhancement technologies in non-invasive BCI and healthcare robot systems, with a focus on addressing long-standing industry challenges, including insufficient EEG signal stability and limited signal decoding accuracy. The collaboration will include system integration validation, engineering testing, and application-oriented exploration, and is intended to lay a technical foundation for the subsequent productization and commercialization of acoustic technologies in rehabilitation training and healthcare service scenarios.

Acoustic Technologies Offer a New Technical Pathway for Non-Invasive BCI

Within the above collaboration framework, Datasea will apply its accumulated capabilities in advanced acoustic technologies to BCI application scenarios, forming a series of acoustic solutions—including sound-wave coupling enhancement mechanisms and real-time closed-loop vibration modulation methods—designed to improve EEG signal acquisition quality, enhance overall system stability, and increase adaptability in complex application environments.

Datasea's exploration of BCI applications represents a natural extension of its core acoustic technologies into the fields of neuromodulation and intelligent interaction, and is consistent with the Company's existing development pathway in healthcare and intelligent application scenarios.

Joint Technical Validation and System-Level Integration Exploration

In accordance with the collaboration agreement, the parties will conduct joint technical testing and application evaluations centered on system integration and engineering validation, with the objective of assessing the feasibility of incorporating acoustic enhancement modules into existing BCI and healthcare robot system architectures.

Nanjing Linghang Intelligent Aviation Technology Co., Ltd. is a high-tech enterprise focused on BCI technologies, healthcare robotics, and scenario-based system solutions. The company has established technical capabilities and practical experience in non-invasive BCI systems, multi-channel EEG signal acquisition, signal processing, system-level engineering validation platforms, and robotic system integration. Its related products and solutions have undergone application validation across hospitals, healthcare centers, elderly care institutions, disability service organizations, and community rehabilitation settings in multiple regions of China.

By integrating Datasea's acoustic enhancement technologies with Linghang Intelligent's existing BCI systems and healthcare robot product foundations, the parties will jointly advance the validation and application exploration of acoustic-enhanced technologies in real-world systems. The introduction of acoustic enhancement is expected to contribute positively to improvements in signal acquisition stability and overall system reliability, thereby providing stronger technical support for the progression of BCI-related technologies toward productization and practical deployment in rehabilitation and healthcare service scenarios.

Market Background

According to industry research reports published in 2024 by Grand View Research and Fortune Business Insights:

• The global brain–computer interface market is expected to exceed USD 15–20 billion by 2030;
• Non-invasive BCI technologies, due to their safety, accessibility, and broader application potential, are anticipated to be the fastest-growing segment;
• Over the next decade, medical rehabilitation, consumer electronics, and intelligent wearable devices are expected to serve as the primary demand drivers.

The Company believes that continued growth in rehabilitation medicine and elderly care services will provide sustained momentum for the long-term research and development, engineering validation, and application exploration of BCI-related technologies.

Management Commentary

Ms. Zhixin Liu, Chief Executive Officer of Datasea, commented:

"We believe that brain–computer interface technology represents an important technical direction with substantial long-term growth potential. Along this path, Datasea has completed the development of acoustic enhancement technology prototypes and patent layouts, including coupling enhancement and real-time closed-loop vibration modulation, and has preliminarily validated the application potential of acoustic technologies in improving signal quality and decoding stability for non-invasive BCI systems.

At present, through our collaboration with Linghang Intelligent, we are introducing these technologies into healthcare robot and BCI system architectures for system-level validation, while simultaneously advancing the development of application-oriented non-invasive BCI products incorporating our acoustic technology strengths. From a technical and application perspective, Datasea is positioned not only to provide critical underlying enhancement solutions to existing BCI systems, but also to progressively develop the potential to deliver proprietary BCI system products.

We view brain–computer interface technology not as a leap into a new field, but as a natural extension of Datasea's acoustic technologies into neuromodulation and intelligent interaction. As validation and development efforts continue, we aim to deliver valuable technical solutions to the rehabilitation and healthcare industries while expanding the Company's long-term growth opportunities and creating sustainable long-term value for shareholders."

About Datasea Inc.

Datasea Inc. ("Datasea") is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company's advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea's control, which may cause Datasea's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea's filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email:  investorrelations@shuhaixinxi.com 
            sunhezhi@shuhaixinxi.com 

Precept Investor Relations LLC
David Rudnick
+1 646-694-8538
david.rudnick@preceptir.com

 

FAQ

What did Datasea (DTSS) announce on January 5, 2026 regarding BCI?

Datasea announced a strategic collaboration with Nanjing Linghang to test acoustic enhancement in non-invasive BCI and healthcare robots.

How will Datasea's acoustic technologies be used in BCI systems (DTSS)?

They plan to apply sound-wave coupling and real-time closed-loop vibration modulation to improve EEG acquisition and decoding stability.

Does the Datasea and Linghang agreement include product development or commercialization (DTSS)?

The parties will conduct system integration and engineering validation to lay a technical foundation for potential productization and commercialization.

What market size did Datasea cite for brain–computer interfaces (DTSS)?

The release cites industry reports projecting the global BCI market at USD 15–20 billion by 2030.

Where have Linghang's BCI and robotics solutions been validated as noted by Datasea (DTSS)?

Linghang's products have undergone application validation in hospitals, healthcare centers, elderly care institutions, and community rehabilitation settings.

What immediate technical goals does the Datasea–Linghang collaboration aim to achieve (DTSS)?

The collaboration targets improved EEG signal stability, enhanced decoding accuracy, and system-level validation in real-world settings.